Key result
Single-dose universal hepatitis A immunization at 1 year of age resulted in 93% of children maintaining seroprotection 4 years later, alongside low viral circulation in unvaccinated infants.
Why the study?
Does single-dose hepatitis A immunization provide persistent immunologic protection up to 4 years in children?
Cross-Sectional (n=1,572)
Does single-dose hepatitis A immunization provide persistent immunologic protection up to 4 years in children?
A single dose of hepatitis A vaccine in infants provides persistent immunologic protection up to 4 years and is associated with low viral circulation in Argentina.
Supports single-dose HAV durability to 4 years; extends observational data but leaves open randomized confirmation.
BACKGROUND: Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children aged 12 months in 2005. Between 2005 and 2011, a dramatic decline was observed in HAV infection rates, fulminant hepatitis, and liver transplantation. This study assessed current viral circulation and estimated protective antibody persistence 4 years after vaccination. METHODS: Prevalence of prevaccination anti-HAV antibodies in 12-month-old children was evaluated as an indirect estimation of viral circulation (Group A). Seroprevalence was also measured in 5-year-old children who received 1 dose of HAV vaccine at 1 year of age (Group B). Blood samples were tested for immunoglobulin (Ig)G anti-HAV antibodies (seroprotection = ≥10 mIU/mL). All Group A-positive samples were tested for IgM anti-HAV antibodies to identify recent infections. Logistic regression analysis was done to evaluate associations between demographic and socioeconomic variables and seroprotection. RESULTS: Of 433 children from Group A, 29.5% (95% confidence interval [CI], 25.2-33.8) were positive for IgG anti-HAV antibodies with a geometric mean concentration (GMC) of 6.17 mIU/mL (95% CI, 5.33-7.15 mIU/mL); all IgM anti-HAV were negative. From 1139 in Group B, 93% (95% CI, 91.7-94.6) maintained seroprotection with a GMC of 97.96 mIU/mL (95% CI, 89.21-107.57 mIU/mL). Kindergarten attendance was associated with seroprotection in Group B (odds ratio [OR], 2.0; 95% CI, 1.26-3.3). In contrast, high maternal educational level was associated with a lack of seroprotection in this group (OR, .26; 95% CI, .09-.8). CONCLUSIONS: Single-dose, universal hepatitis A immunization in infants resulted in low HAV circulation and persistent immunologic protection up to 4 years in Argentina. Variables associated with presence or absence of seroprotection in vaccinated children could be related to differences in hygiene habits in settings with residual viral circulation.
No takes yet. Share an insight, caveat, or question.
Vizzotti et al. (2014) conducted a cross-sectional in Hepatitis A (n=1,572). Single-dose hepatitis A virus (HAV) vaccination vs. Unvaccinated 12-month-old children was evaluated on Maintenance of seroprotection (IgG anti-HAV ≥10 mIU/mL) at 4 years post-vaccination. Single-dose universal hepatitis A immunization at 1 year of age resulted in 93% of children maintaining seroprotection 4 years later, alongside low viral circulation in unvaccinated infants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: